trending Market Intelligence /marketintelligence/en/news-insights/trending/xomkuml72eyxacskuso39w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Amgen to invest £50M in UK DNA sequencing company

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Amgen to invest £50M in UK DNA sequencing company

Amgen Inc. will invest £50 million in Oxford Nanopore Technologies Ltd., a privately owned company developing portable, real-time genetic sequencing technology.

U.K.-based Oxford Nanopore specializes in scalable technologies for DNA sequencing, where a sample is studied to determine the arrangement within a complex structure of nucleotides, the building blocks of DNA and RNA.

Iceland-based deCODE Genetics, a subsidiary of Amgen, already uses Oxford Nanopore's technology in its genome research.

"Oxford Nanopore's long-read sequencing capability creates a window into parts of the genome that have been out of reach, as well as giving us a much better handle on structural variants that confer risk of a wide variety of diseases," said deCODE Genetics Founder Kári Stefánsson. "We have used Oxford Nanopore technology to sequence several hundred human genomes and continue to see the promise of this emerging technology."

Thousand Oaks, Calif.-based Amgen produces a range of drugs for serious illnesses, including heart diseases, inflammation, bone problems and conditions of the nervous system.